Daily Stock Analysis, CBAY, CymaBay Therapeutics Inc, priceseries

CymaBay Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
12.46
Close
12.07
High
12.70
Low
11.86
Previous Close
12.30
Daily Price Gain
-0.23
YTD High
15.59
YTD High Date
Mar 5, 2018
YTD Low
8.82
YTD Low Date
Jan 2, 2018
YTD Price Change
3.07
YTD Gain
34.11%
52 Week High
15.59
52 Week High Date
Mar 5, 2018
52 Week Low
3.16
52 Week Low Date
Apr 27, 2017
52 Week Price Change
8.51
52 Week Gain
239.04%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
1.90
Jan 12. 2017
2.02
7 Trading Days
6.58%
Link
LONG
Feb 7. 2017
2.05
Mar 21. 2017
3.97
29 Trading Days
93.65%
Link
LONG
May 24. 2017
3.96
Jun 6. 2017
4.37
8 Trading Days
10.27%
Link
LONG
Jun 15. 2017
4.62
Jul 10. 2017
5.58
16 Trading Days
20.71%
Link
LONG
Sep 11. 2017
6.27
Oct 2. 2017
7.74
15 Trading Days
23.52%
Link
LONG
Dec 15. 2017
8.32
Jan 9. 2018
9.06
15 Trading Days
8.92%
Link
LONG
Jan 18. 2018
10.14
Feb 5. 2018
11.57
12 Trading Days
14.11%
Link
LONG
Feb 12. 2018
12.25
Mar 1. 2018
14.41
12 Trading Days
17.65%
Link
Company Information
Stock Symbol
CBAY
Exchange
NasdaqCM
Company URL
http://www.cymabay.com
Company Phone
510-293-8800
CEO
Sujal Shah
Headquarters
California
Business Address
7999 GATEWAY BLVD, SUITE 130, NEWARK, CA 94560
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001042074
About

CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate. MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Description

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.